| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11307-014-0800-X |
| P698 | PubMed publication ID | 25315836 |
| P50 | author | Seyed Rasoul Zakavi | Q40301508 |
| P2093 | author name string | Christian Schiller | |
| Andrew Stephens | |||
| Ludger Dinkelborg | |||
| Mohsen Beheshti | |||
| Wolfgang Loidl | |||
| Werner Langsteger | |||
| Thomas Kunit | |||
| Silke Haim | |||
| P2860 | cites work | Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer | Q44192340 |
| Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues | Q44962356 | ||
| High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer | Q44994966 | ||
| Positron tomographic assessment of androgen receptors in prostatic carcinoma | Q45279143 | ||
| First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer | Q45868903 | ||
| A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer | Q46181868 | ||
| Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer | Q46685936 | ||
| Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. | Q51737133 | ||
| PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. | Q51766972 | ||
| Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. | Q53114228 | ||
| PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. | Q53131398 | ||
| [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. | Q53527477 | ||
| Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. | Q53572699 | ||
| Prostate-specific membrane antigen expression in normal and malignant human tissues | Q77553386 | ||
| Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature | Q28139062 | ||
| Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer | Q28236013 | ||
| Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer | Q28254156 | ||
| Expression of glutamate carboxypeptidase II in human brain | Q28277506 | ||
| Prostate-specific membrane antigen expression as a predictor of prostate cancer progression | Q28289877 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 | ||
| Constitutive and antibody-induced internalization of prostate-specific membrane antigen. | Q32015731 | ||
| Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer | Q33361082 | ||
| Tissue microarray technology for high-throughput molecular profiling of cancer | Q34188970 | ||
| Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT | Q34995973 | ||
| A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy | Q35544056 | ||
| Fluorocholine PET/CT in patients with prostate cancer: initial experience | Q36109495 | ||
| Recent Advances and Future Advances in Time-of-Flight PET | Q36157177 | ||
| Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. | Q36619673 | ||
| Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. | Q37325974 | ||
| State of the art and challenges of time-of-flight PET. | Q37356191 | ||
| Promising tumor-associated antigens for future prostate cancer therapy. | Q37523602 | ||
| Prostate cancer: role of SPECT and PET in imaging bone metastases | Q37607846 | ||
| 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients | Q37696901 | ||
| PET imaging in prostate cancer: focus on prostate-specific membrane antigen | Q38099369 | ||
| A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. | Q39336427 | ||
| 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy | Q39523112 | ||
| 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer | Q39689821 | ||
| Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids | Q41297571 | ||
| A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer | Q41600550 | ||
| N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer | Q41913170 | ||
| Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases | Q42456087 | ||
| Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer | Q43193122 | ||
| Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer | Q43478484 | ||
| Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. | Q43860792 | ||
| P433 | issue | 3 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 424-433 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Molecular Imaging and Biology | Q6895951 |
| P1476 | title | BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study) | |
| P478 | volume | 17 |
| Q92423926 | 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging |
| Q57171336 | Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications |
| Q38379159 | Lymph node staging in prostate cancer. |
| Q37390674 | Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer |
| Q26799439 | Prostate-specific membrane antigen as a target for cancer imaging and therapy |
| Q38737674 | Small-molecule PSMA ligands. Current state, SAR and perspectives. |
| Q28074669 | Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging |
| Q39780216 | Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent |
Search more.